Melissa M. Hardesty, MD, discusses OS and subgroup data from the OVARIO study of niraparib and bevacizumab maintenance in newly diagnosed ovarian cancer.
Melissa Hardesty, MD
Advertisement
Articles by Melissa Hardesty, MD
Melissa Hardesty, MD, gynecologic oncologist, Alaska Women’s Cancer Center, discusses the safety and efficacy of the bevacizumab/PARP inhibitor combination in ovarian cancer.
Melissa Hardesty, MD, gynecologic oncologist, Alaska Women’s Cancer Center, discusses second-line maintenance therapy after frontline chemotherapy for patients with ovarian cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC
3
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
4
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
5